GÜNER AKGÜNER

Dr. GÜNER AKGÜNER

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GAGÜNER AKGÜNER
GÜNER AKGÜNER
MAMustafa Altınbaş
Mustafa Altınbaş
Background and objective: The CALLY index has been recognized as a prognostic biomarker across various malignancies; however, its prognostic utility in metastatic renal cell carcinoma (mRCC) has not been extensively characterized. This study aimed to elucidate the prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in patients diagnosed with mRCC. Methods: In this retrospective multicenter study, patients with metastatic renal cell carcinoma were included. Demographic and disease-related data were collected. The CALLY index was calculated as follows: serum albumin level (g/dL) × absolute lymphocyte count (cells/µL)/C-reactive protein (CRP) (mg/dL) × 104. The optimal cut-off value for the CALLY index was determined using maximal log-rank analysis. Overall survival and progression-free survival analyses were performed according to the cut-off value, and Cox regression analyses were conducted to identify factors affecting prognosis. Results: A total of 95 patients were included in the present study. The prognostic cut-off value for the CALLY index was determined as 0.12. The median overall survival (OS) was 11.1 months (95% CI 6.7–15.4) in the CALLY index < 0.12 group, compared to 45.7 months (95% CI 31.6–59.8) in the CALLY index ≥ 0.12 group (p < 0.001). Similarly, the median progression-free survival (PFS) was 7.1 months (95% CI 4.5–13.2) in the CALLY index < 0.12 group and 33.1 months (95% CI 17.2–48.1) in the CALLY index ≥ 0.12 group (p < 0.001). In Cox regression analysis, a CALLY index < 0.12 was identified as an independent prognostic factor for shorter OS (HR: 0.41, 95% CI 0.22–0.76, p = 0.004) and PFS (HR: 0.40, 95% CI 0.23–0.69, p = 0.001). Conclusion: The CALLY index was identified as an independent prognostic biomarker in metastatic renal cell carcinoma. Prospective large-scale studies are needed to confirm its clinical utility.

1 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
GUGalip Uyar
Galip Uyar
GAGÜNER AKGÜNER
GÜNER AKGÜNER
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
SKSeher KAYA
Seher KAYA
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background: Systemic inflammation and nutritional status are key determinants of prognosis in metastatic clear-cell renal carcinoma (mccRCC). Composite indices such as the Systemic Immune–Inflammation Index (SII) and the Modified Glasgow Prognostic Score (mGPS) have demonstrated prognostic relevance across cancers, but real-world data in mccRCC remain limited. Methods: This retrospective, single-center cohort included patients with histologically confirmed mccRCC who received first-line tyrosine kinase inhibitor (TKI) monotherapy (sunitinib, pazopanib, or cabozantinib) between November 2022 and November 2024 at Etlik City Hospital (Ankara, Türkiye). Associations between inflammatory–nutritional indices (SII, mGPS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable logistic regression analyses. Results: A total of 55 patients met eligibility criteria and were included in the analysis. The median age was 62 years (IQR 52–71), and 67% were male. Median PFS was 13.24 months (95% CI 7.75–19.12), while median OS was not reached. High SII (≥ 870) was independently associated with shorter PFS in multivariable analysis (OR 5.05; 95% CI 1.14–15.77; p = 0.039). mGPS (1–2) was significantly associated with inferior PFS in Kaplan–Meier analysis (HR 3.43; 95% CI 1.42–8.30; p = 0.006; log-rank p = 0.001), but lost significance in multivariable modeling. Metformin use (OR 0.12; 95% CI 0.02–0.93; p = 0.044), sunitinib therapy (OR 0.07; 95% CI 0.006–0.74; p = 0.027), and favorable/intermediate IMDC risk group (OR 0.17; 95% CI 0.06–0.96; p = 0.047) were independently associated with a lower progression risk. Patients treated with cabozantinib (n = 15) showed a numerically longer median PFS (18.6 months; 95% CI 13.8–23.3) compared with sunitinib (n = 25, 12.2 months; 95% CI 5.5–19.0) and pazopanib (n = 15, 12.1 months; 95% CI 6.7–17.5), although this difference was not statistically significant (log-rank p = 0.152). Conclusion: In this real-world cohort of patients with mccRCC treated with first-line TKI, host-related inflammatory and nutritional status were closely associated with progression-free survival. Additionally, patients classified within the favorable IMDC risk group exhibited a significantly lower risk of progression, highlighting the importance of integrating clinical risk stratification with systemic inflammatory and nutritional markers. Incorporating such easily measurable biomarkers and clinical risk scores into existing prognostic models may enhance individualized risk assessment and therapeutic decision-making. Future prospective, multicenter, randomized controlled, and artificial intelligence–assisted studies are warranted to validate these findings and refine precision oncology approaches in this population.

28 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
HŞHayriye Şahinli
Hayriye Şahinli
GUGalip Uyar
Galip Uyar
SÇselahattin çelik
selahattin çelik
SKSalih Karatlı
Salih Karatlı
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
Background and Objectives: The effect of bevacizumab on the morphology of non-tumoral organs remains unclear. We evaluated computed tomography (CT)- derived treatment-emergent pancreatic volume loss and examined its association with progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer receiving bevacizumab. Materials and Methods: This single-center retrospective study included 105 patients treated at Ankara Etlik City Hospital who had evaluable paired contrast-enhanced CT scans obtained before and during therapy. Pancreatic volume was measured on CT, and percentage volume loss was calculated. Clinical, laboratory, radiological, and survival data were retrospectively reviewed. Results: Mean pancreatic volume declined from 89.9 ± 6.1 mL before treatment to 83.6 ± 5.1 mL during therapy (p < 0.001). Albumin levels and platelet counts also decreased, whereas amylase, hemoglobin, and the neutrophil-to-lymphocyte ratio remained largely unchanged. In the main multivariable models, each 1% increase in pancreatic volume loss was associated with worse bevacizumab-line PFS (HR 1.06, 95% CI 1.02–1.10; p = 0.032) and OS (HR 1.08, 95% CI 1.01–1.15; p = 0.041). Percentage change in albumin was independently associated with both endpoints. Sensitivity analyses supported a more consistent association of pancreatic volume loss with PFS than with OS. Conclusions: Pancreatic volume decreased during bevacizumab-containing therapy. Greater pancreatic volume loss was associated with shorter PFS and OS; however, the association was more consistent for PFS. Prospective studies are needed to validate these findings and determine their clinical relevance.

7 August 2025
Verified
Book
Open access
PDF file
ŞSŞermin Dinç Sonuşen
Şermin Dinç Sonuşen
IBİbRahim Bilen
İbRahim Bilen
ÖKömer Faruk Kuzu
ömer Faruk Kuzu
ÖDÖzden Demir
Özden Demir
HBHülya Odabaşı bükün
Hülya Odabaşı bükün
MKMerve Köse
Merve Köse

11 March 2024
Verified
Book
Open access
PDF file
ASAyşegül Sakin
Ayşegül Sakin
KKKubilay Karaboyun
Kubilay Karaboyun
JHJamshid Hamdard
Jamshid Hamdard
SYSaadet Sim Yıldırım
Saadet Sim Yıldırım
MÖMerve Özkan
Merve Özkan
ŞSŞaban Seçmeler
Şaban Seçmeler
Klinik Araştırma Türleri Ayşegül SAKİN Geleneksel Çin Tıbbı Kubilay KARABOYUN Ginseng Jamshid HAMDARD Zerdeçal Ekstresi (Kurkumin/Turmeric) Saadet SİM YILDIRIM Kara Kohoş Otu (Cimicifuga Racemosa) Merve ÖZKAN Ekinezya (Echinacea Purpurea) Abdussamet ÇELEBİ Gingko Biloba Mert ERCİYESTEPE Flavonoidler Aslı GEÇGEL Yeşil Çay (Camellia Sinensis) Berkan KARABUĞA Ada Çayı (Salvıa Offıcınalıs) Seval ORMAN Essiac Çayı Shamkhal SAFAROV Çörek Otu (Nigella Sativa) Özden DEMİR Deve Dikeni (Silybum Marianum) Gamze SERİN ÖZEL Isırgan Otu (Urtica Dioica) Gülhan DİNÇ Andız (Inula Viscoza) Azer GÖKMEN Garcinol (Garcinia Cambogia) Serkan GÜLCÜ Nar kabuğu (Punica Granatum) Orçun CAN Kişniş (Coriandrum Sativum) Nurbanu İNCİ Biberiye (Rosmorinus Officinalis) Pınar ÇOBAN EŞDUR Zencefil (Zingber Officinale) Nadiye SEVER Nane (Mentha Piperita) Okan AYDIN Papatya (Chammomilla Recutita) Buket ŞAHİN ÇELİK Zeytinyağı (Virgin Olive Oil) Hayriye TANİN DEMİRCİ Kekik (Thymus/ Thyme/ Thymus Vulgaris) Ahmet Emin ÖZTÜRK Ökse Otu (Mistletoe) Hacı ARAK Keçiboynuzu (Ceratonia Siliqua) Murad GULIYEV Hurma (Phoenix Dactylifera) Akif DOĞAN İncir (Ficus Carica) Erkam KOCAASLAN Sarımsak (Allium Sativum) ve Soğan (Allium Cepa) Ahmet AYDIN Sabin GÖKTAŞ AYDIN Kava Kava (Piper Methysticum) Yıldız GARİP BİLEN Meyan kökü (Glyctrrhiza Uralensis) Altay ALİYEV Sarı Kantaron (Hypericum Perforatum) Mustafa ERSOY Kedi Otu (Valeriana Officinalis) Mürsel SALİ Geven Otu (Astragalus) Harun MUĞLU Aloe Vera Emir Gökhan KAHRAMAN Kenevir (Cannabis) Alperen Akansel ÇAĞLAR Graviola Meyvesi ve Yaprağı (Annona Muricata Leaf) Seda SALİ Reişi Mantarı (Reishi Shiitake Maitake) Alper COŞKUN Likopen (Solanum Lycopersicum) Oğuzcan ÖZKAN Modifiye Narenciye Pektini (Pectin) Sümeyra DERİN Bayır Turbu (Armoracia Rusticana) Yasin SEZGİN Akgünlük (Boswellia Serrata) Esra Şazimet KARS Balık Yağı / Omega Yağları Nargiz MAJİDOVA Melatonin Aykut TURHAN Köpekbalığı Kıkırdağı Ömer GENÇ Hidrazin Doğan BAYRAM Koenzim Q10 Ekin KONCA KARABUĞA Resveratrol İbrahim BİLEN Timus Ekstresi Mehmet Cem FİDAN Bal ve Propolis Eyüp ÇOBAN Mineral Takviyesi Ömer Faruk ELÇİÇEK Kefir ve Kanser Melek ÖZDEMİR Alfa Lipoik Asit Hülya ODABAŞI BÜKÜN Glutatyon Fatma Pınar AÇAR Mavi Akrep Zehiri (Rhopalurus Junceus) Muslih ÜRÜN Spirulina Özge YALICI Chlorella Şermin DİNÇ SONUŞEN C Vitamini (Askorbik Asit) Murat GÜNALTILI Vitamin D Yunus Emre ALTINTAŞ A Vitamini ve Karotenler Tanju KAPAĞAN Vitamin E Güner AKGÜNER B6 Vitamini (Pridoksin) Erdem SÜNGER B12 Vitamini (Kobalamin) Goncagul AKDAG Folik Asit Selen KANTARCI KARATAŞ Multivitamin Kompleksleri Ezgi TÜRKOĞLU Ketojenik Diyet Ömer Faruk KUZU Akdeniz Diyeti Osman Bilge KAYA Aralıklı Oruç Ülviye OFLAS Vegan Beslenme Oğuzcan KINIKOĞLU Akupunktur Tedavisi Gülin Alkan ŞEN Yoga/Meditasyon Mehmet Nezir RAMAZANOĞLU Hypnotherapy Zeynep ALTUNDAĞ DERİN Aromatherapy Pınar PEKER Ayurveda Salih TÜNBEKİCİ Hacamat (Cupping Therapy) Mahmut KARA Ozon Tedavisi Murat ALAN üm Vücut Hipertermi (Whole Body Hyperthermia) Şaban SEÇMELER

7 August 2025
Verified
Book Chapter
Closed access
GAGÜNER AKGÜNER
GÜNER AKGÜNER
Kaposi Sarkomu (KS) endotel hücrelerinin multifokal malignitesi olup Kaposi Sarkomu ilişkili Herpesvirüs’le sıkı bir ilişkisi mevcuttur. AIDS ilişkili, endemik, klasik ve iyatrojenik ya da transplantasyon ilişkili dört tipi vardır. HIV(+) hastalarda HIV enfeksiyonunun yönetimi KS tedavisinde önemlidir. Lokal tedaviler, kemoterapi, immünoterapi gibi sistemik tedaviler, radyoterapi tedavide kullanılmaktadır. Hastaların takibinde anamnez, detaylı fizik muayene, laboratuvar testleri önemli olup, sistemik hastalık, progresif/refrakter hastalık varlığında takiplerde ek olarak radyolojik görüntüleme yöntemleri (X-RAY, BT, MRI, PET-BT) de kullanılmaktadır. HIV(+) vakalarda HIV tedavisinin yönetimi ve takibi KS tedavisinde önemlidir. Kaposi Sarcoma (KS) is a multifocal malignancy of endothelial cells and is strongly associated with Kaposi's Sarcoma-associated Herpesvirus (KSHV). There are four types of KS: AIDS-related, endemic, classic, and iatrogenic or transplant-associated. In HIV-positive patients, the management of HIV infection plays a critical role in the treatment of KS. Treatment modalities include local therapies, chemotherapy, immunotherapy, and radiotherapy. During patient follow-up, taking a detailed medical history, conducting thorough physical examinations, and performing laboratory tests are crucial. Additionally, in the presence of systemic or progressive/refractory disease, radiological imaging methods such as X-ray, CT, MRI, and PET-CT are also utilized. The management and monitoring of HIV treatment are essential components in the management of KS in HIV-positive patients.